For metabolically stable adults receiving TPN, the suggested additive dosage level is 20 to 120 mcg molybdenum/day. For pediatric patients, the additive dosage level should be calculated by extrapolation. In an adult, molybdenum deficiency state resulting from prolonged TPN support, intravenous administration of molybdenum as ammonium molybdate at 163 mcg/day for 21 days has been reported to reverse deficiency symptoms without toxicity.

Human prostate cancer cell line PC-3 were used for activity evaluation. PC-3 cells were plated onto 3.5-cm Petri dishes, incubated at 37 C for 24 h and treated with or without the Molybdate (2.0 mM) in the medium containing 10% FBS. At different time points, cells were washed twice with cold PBS– EDTA. Both floating and adherent cells were collected by trypsinization and centrifugation at 1,200g for 8 min. The cells were then fixed in 80% ethanol (-20 _C). Before analysis, the supernatant was removed by centrifugation at 2,000g for 5 min. Cells were washed once in cold PBS– EDTA, collected by centrifugation at 1,200g for 5 min, and resuspended in PBS–EDTA containing 40 lg/ml propidium iodide and 100 lg/ml ribonuclease A. The cell cycle distribution was analyzed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) using CellQuest Pro (BD Biosciences).